Patient & Survivor Care
Feature
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
Researchers examine links between mortality risk and health-related social needs in patients who had cancer.
From the Journals
Terminal Cancer: What Matters to Patients and Caregivers
Patients and caregivers are less aligned on decisions about cost containment than end-of-life goals.
From the Journals
MicroRNAs May Predict Pancreatic Cancer Risk Years Before Diagnosis
Researchers screen and validate circulating miRNAs as biomarkers for early detection using prediagnostic plasma samples.
Feature
The Long, Controversial Search for a ‘Cancer Microbiome’
Research raised as many questions as answers about what we do and don’t know about microbiota and cancer.
From the Journals
Potential Cure for Early BRCA-Mutated Breast Cancer?
All patients who recieved a combination of standard chemotherapy with olaparib were alive at 36 months.
Feature
Routine Breast Cancer Screening Should Start at Age 40: USPSTF
Three JAMA editorials address concerns about the new recommendations.
From the Journals
Could Aspirin Help Treat Breast Cancer?
Researchers conduct first randomized, placebo-controlled trial of aspirin in survivors of breast cancer.
From the Journals
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Researchers estimate more than 9,000 survivors’ adherence to weight, physical activity, fruit and vegetable consumption, and alcohol intake...
Commentary
‘We Need to Rethink Our Options’: Lung Cancer Recurrence
“Suddenly, we have better tools to control systemic spread.”
Conference Coverage
Can Rectal Cancer Patients Benefit from Deintensification of Treatment?
An expert at the National Comprehensive Cancer Network annual conference discussed treatment-sparing strategies for eligible patients.
Conference Coverage
Is Osimertinib Better Alone or With Chemotherapy in Non–Small Cell Lung Cancer?
Randomized trial of 557 patients compares taking osimertinib alone to osimertinib with pemetrexed plus cisplatin or carboplatin, followed by...